Lunsumio (mosunetuzumab) is an immunotherapy approved for adults with relapsed or refractory follicular lymphoma after two or more prior lines of treatment. It works by helping the immune system target and attack lymphoma cells.
In terms of effectiveness, it was significant enough to earn FDA approval, which means it Show Full Answer
Lunsumio (mosunetuzumab) is an immunotherapy approved for adults with relapsed or refractory follicular lymphoma after two or more prior lines of treatment. It works by helping the immune system target and attack lymphoma cells.
In terms of effectiveness, it was significant enough to earn FDA approval, which means it showed meaningful results in clinical trials for follicular lymphoma patients whose cancer had returned or stopped responding to earlier treatments. As an immunotherapy, Lunsumio can cause side effects that are common to this class of treatment. These may include:
- Fever or chills
- Fatigue
- Nausea
- Headaches
- Body aches
- Skin reactions like rash or itchiness
- Shortness of breath
More serious side effects to be aware of include:
- Cytokine release syndrome (CRS) – a sudden, intense flu-like reaction
- ICANS – a brain-related side effect that can affect speech, balance, or thinking
- Inflammation in organs like the lungs, colon, thyroid, kidneys, or liver
Your healthcare team will monitor you closely, especially during the first two weeks after treatment. Always report any new or worsening symptoms to them right away.
August 2
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
